Invest

Primary contacts

Magnus Stuart, CFO
+46 70 321 13 50
magnus.stuart@prosmedic.se

Hans-Henrik Bark
+46 70 839 82 83
hh.bark@prosmedic.se

Reason to invest

Eliminate overtreatment that costs our society millions

There is an urgent need for a simple test suited for prostate cancer screening. Far too many operations for prostate cancer have been unnecessary. With the ExoPro test this will be avoided and estimated reduction for treatment will be around 50%

Stop unnecessary suffering and revolutionize cancer care

Overtreatment is not only costly, it also puts people through unnecessary suffering. Waiting for a diagnosis, regardless of the outcome, is extremely stressful. It is also a fact that the early detection of cancer is the key to successful treatment. With the ExoPro on the market, it will be more feasible to open up for broader screening, and even self-testing at home.

A completely unique solution

ProsMedic’s method is unique and protected by patents.

40 years of research

ProsMedic’s solution is the product of over 40 years of dedicated research.

How it works

Key numbers

1 blood sample

One blood sample is all needed to detect prostate cancer.

More years to live

Patients live longer on average when cancer diagnosis is made early. This is the reason behind screening.

About ProsMedic

Quick facts

  • ProsMedic is a public Swedish company founded in November 2017.
  • The shares are Euroclear registered.
  • ProsMedic´s method is R&D classified.
  • No regulatory certificate is needed from Läkemedelsverket (Swedish Medical Products Agency) or others.
  • ProsMedic started IVDR certification process in August 2022